Published online Mar 16, 2021. doi: 10.12998/wjcc.v9.i8.1989
Peer-review started: November 16, 2020
First decision: December 24, 2020
Revised: January 5, 2021
Accepted: January 8, 2021
Article in press: January 8, 2021
Published online: March 16, 2021
Processing time: 104 Days and 21 Hours
Laryngeal contact granuloma (LCG) is difficult to treat and frequently associated with high persistence and recurrence, despite the availability of both surgical and pharmacological treatment options. An appropriate strategy is therefore needed to help patients with multiple recurrences of LCG to potentially avoid unnecess-ary surgery.
We describe the case of a 34-year-old male patient with recurrent LCG in which a good response was achieved through successful management of laryngophar-yngeal reflux disease using a combination pharmacotherapeutic regimen consisting of anti-reflux therapy, pepsin secretion inhibition, bile acid neutralization, and lifestyle modifications. This patient underwent surgery to excise the granuloma, then relapsed, underwent a second surgery, which was followed by a second recurrence. The granuloma then disappeared after 9 mo of combined treatment with ilaprazole enteric-coated capsules (10 mg qd), mosapride tablets (5 mg tid) and compound digestive enzyme capsules (2 tablets). The drug regimen was discontinued after one year, and no recurrence of the lesion has been reported during the one-year follow-up period.
We report a combination of pharmacotherapeutics and lifestyle modifications for the management of laryngopharyngeal reflux disease to address recurring LCG.
Core Tip: Laryngeal contact granuloma (LCG) is difficult to treat and frequently associated with high persistence and recurrence. We describe a patient with recurrent LCG in which a good response was achieved through successful management of laryngopharyngeal reflux disease using a combination pharmacotherapeutic regimen consisting of anti-reflux therapy, pepsin secretion inhibition, bile acid neutralization, and lifestyle modifications. The drug regimen was discontinued after one year, and no recurrence was observed during the one-year follow-up period. This case report highlights the efficacy of combined pharmacotherapeutics and lifestyle modifications in managing laryngopharyngeal reflux disease to address recurring LCG.